Industry Overview

Geriatric medicine market was valued at $177.6 billion in 2025 and is projected to reach $348.6 billion by 2035, growing at a CAGR of 7.0% during the forecast Period (2026-2035). The market focuses on the prevention, diagnosis, and treatment of age-related health conditions in elderly populations. It encompasses a range of therapeutic areas, including cardiovascular diseases, neurological disorders, arthritis, diabetes, cancer, and respiratory illnesses. Growth in this market is driven by the increasing aging population, rising prevalence of chronic diseases, and advancements in drug development and healthcare infrastructure. The market also benefits from innovations in targeted therapies, personalized care, and supportive treatment solutions tailored for older adults.

Market Dynamics

Rapidly Increasing Aging Population

One of the primary drivers of the global geriatric medicine market is the significant rise in the elderly population worldwide. According to global estimates, the population aged 60 years and above is expected to exceed 2 billion by 2050, driven by increasing life expectancy and declining birth rates. This demographic transition is creating a substantial demand for age-specific healthcare services and medications, as older individuals require continuous medical attention and treatment for various age-related conditions. As a result, pharmaceutical companies and healthcare providers are increasingly focusing on geriatric therapeutics, thereby accelerating market growth.

Rising Prevalence of Chronic Diseases

The growing burden of chronic diseases among the elderly population is another key factor driving the market. Older adults are highly susceptible to conditions such as cardiovascular diseases, diabetes, arthritis, osteoporosis, and neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. A large proportion of the geriatric population suffers from multiple chronic conditions simultaneously, leading to increased dependence on long-term medication and polypharmacy. This sustained demand for continuous treatment and disease management significantly boosts the consumption of geriatric medicines and supports overall market expansion.

Increasing Healthcare Expenditure and Government Initiatives

Rising healthcare spending and supportive government initiatives aimed at improving elderly care infrastructure are further propelling market growth. Governments across various countries are investing in geriatric healthcare services, including specialized hospitals, rehabilitation centers, and home care solutions. Additionally, policies promoting early diagnosis, preventive care, and access to affordable medicines are enhancing treatment adoption among older populations. Improved healthcare access, particularly in emerging economies, is enabling a larger elderly population to receive proper medical care, thereby driving demand for geriatric medicines globally.

Market Segmentation

• Based on the therapeutics, the market is segmented into analgesics, antihypertensives, statins, antidiabetics, proton pump inhibitors (PPIs), anticoagulants, antipsychotics, and others.
• Based on the condition, the market is segmented into cardiovascular diseases, arthritis & bone health, neurological disorders, cancer (geriatric oncology), diabetes & metabolic disorders, respiratory diseases, and others.
• Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Antihypertensive Segment to Grow at a Considerable Market Share

Antihypertensive drugs are expected to hold the largest share in the global geriatric medicine market. This dominance is primarily driven by the high prevalence of hypertension among the elderly population worldwide. Hypertension is one of the most common chronic conditions in individuals aged 60 years and above, significantly increasing the risk of cardiovascular complications such as heart attack, stroke, and kidney disease.

With aging, arterial stiffness and other physiological changes make older adults more susceptible to elevated blood pressure, thereby necessitating long-term and often lifelong medication. As a result, antihypertensive drugs witness consistent and high-volume demand compared to other therapeutic categories. Additionally, clinical guidelines strongly emphasize early diagnosis and continuous management of blood pressure in geriatric patients, further reinforcing the widespread use of these medications.

The segment’s leadership is also supported by the availability of multiple drug classes, including ACE inhibitors, beta-blockers, calcium channel blockers, and diuretics, enabling personalized treatment approaches. Moreover, increasing awareness, improved screening rates, and expanding access to healthcare services globally are contributing to higher diagnosis and treatment rates.

Overall, the chronic nature of hypertension, combined with its widespread occurrence and need for sustained therapy, firmly establishes antihypertensives as the leading segment in the geriatric medicine market.

Cardiovascular Diseases: A Key Segment in Market Growth

The cardiovascular diseases (CVDs) represent the fastest-growing segment in the global geriatric medicine market. The prevalence of CVDs increases sharply with age, making it a critical concern for the elderly population. Older adults are more susceptible to conditions such as hypertension, coronary artery disease, heart failure, and arrhythmias, often requiring long-term pharmacological management. According to recent epidemiological data, cardiovascular diseases remain the leading cause of mortality among individuals aged 60 and above, accounting for nearly one-third of deaths in this age group globally.

The rising prevalence of risk factors, including obesity, sedentary lifestyles, and diabetes, further amplifies demand for cardiovascular therapeutics in geriatrics. Pharmaceutical advancements, such as fixed-dose combination therapies, novel anticoagulants, and heart failure management drugs, are specifically tailored to improve compliance and efficacy among elderly patients, boosting market adoption. Moreover, the increasing number of hospitalizations due to CVD complications drives higher consumption of prescribed medications, particularly in hospital and retail pharmacy channels. Government initiatives focusing on cardiovascular health awareness, early detection, and preventive care are also supporting market growth. Overall, the cardiovascular segment not only dominates in terms of revenue but is expected to continue expanding at a robust pace, driven by the aging global population and the high burden of cardiovascular conditions among the elderly.

Regional Outlook

The global geriatric medicine market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global geriatric medicine market, holding a major share due to its  advanced healthcare infrastructure, high geriatric population, and strong focus on research and innovation in age-related therapeutics. The country has one of the largest elderly populations globally, with a growing proportion of individuals aged 65 and above, creating significant demand for medicines targeting chronic conditions such as cardiovascular diseases, diabetes, neurological disorders, and cancer. This demographic trend has resulted in increased healthcare spending, higher adoption of prescription medications, and continuous investment in geriatric-focused drug development.

Moreover, the US benefits from well-established distribution channels, including hospital and retail pharmacies, along with a rapidly growing online pharmacy sector, ensuring easy access to geriatric medicines across urban and rural regions. Strong regulatory support, coupled with ongoing advancements in pharmaceutical research, has led to the development of novel therapies, age-appropriate drug formulations, and personalized medicine approaches for older adults. Public awareness campaigns and preventive healthcare initiatives also contribute to earlier diagnosis and better management of chronic diseases, boosting medication utilization. Collectively, these factors position the United States as the dominant market for geriatric medicines, setting the benchmark for innovation, accessibility, and overall market growth globally.

Market Players Outlook

The major companies operating in the global geriatric medicine market include AbbVie Inc., AstraZeneca PLC, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In February 2026, MGM Healthcare introduced Swayam, a comprehensive geriatric programme in Chennai designed on a structured continuity-of-care model. The programme focuses on chronic disease management, polypharmacy review, cognitive assessment, rehabilitation support, and fall prevention, complemented by a dedicated helpline for seniors. It encompasses a thorough geriatric assessment and integrates outpatient services, specialized inpatient wards, and hospital-to-home care through remote monitoring and follow-up services.
• In October 2025, Hamad Medical Corp. launched a new Acute Geriatric Care Service at Aisha Bint Hamad Al Attiyah Hospital, focusing on comprehensive multidisciplinary care for patients aged 60 and above with acute health issues like falls and dementia. The service emphasizes a safe environment that addresses the patients' physical, psychological, and social needs, delivered by a team of specialists including geriatric consultants and nursing staff, ensuring personalized care and ongoing support throughout recovery.
• In August 2025, P. D. Hinduja Hospital & Medical Research Centre inaugurated a dedicated Geriatric Clinic on World Senior Citizens Day 2025 to provide comprehensive care for the growing elderly population in India. Its projections showing that over 20% of the population will be 60 or older by 2050, the clinic addresses unique health challenges such as chronic conditions, mobility issues, and cognitive decline. It offers preventive and curative guidance to seniors, including health packages and home visit services tailored for older adults.
• In October 2024, Fortis Gurugram launched a dedicated Geriatric Clinic tailored for individuals aged over 60, aimed at promoting healthy aging and specialized elderly care. The clinic features a helpline for seniors to book appointments and access counseling for health concerns. Services include comprehensive care for age-related ailments, preventive measures such as vaccinations, and screenings for bone health and cancer. Patients can consult on various issues, including mobility, nutrition, and chronic conditions like hypertension and diabetes. The clinic also offers emergency and acute care for serious medical needs.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global geriatric medicine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.